Confirmed Delta Variant COVID-19 Infection at A Single Centre Tertiary Hospital: A Case Series

Authors

  • Sally Aman Nasution Division of Cardiology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
  • Muhadi Muhadi Division of Cardiology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
  • Eric Daniel Tenda Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.

Keywords:

COVID-19, delta variant, vaccination status, variant of concern

Abstract

SARS-CoV-2 continues to mutate with the emergence of new variants. Variant B.1.617.2 (Delta) is a variant of concern with evidence of increased transmission, more severe disease, decreased effectiveness of treatment or vaccines, or failure of diagnostic detection. In this article, we report on the clinical and biological picture of the first confirmed delta variant COVID-19 infection in Indonesia. From May 31 to June 17, we identified ten cases with confirmed delta variant COVID-19 infection admitted to a tertiary academic hospital in Jakarta. All subjects that have been vaccinated presented with mild-moderate disease. Most patients present with initial respiratory complaints, without radiological abnormalities on chest x-ray examination, and an increase in C-reactive protein. Seven out of ten patients have been vaccinated; the three patients who had not been vaccinated experienced severe COVID-19 symptoms, two of whom died. Due to the increased transmission of this variant, we recommend vaccination, wearing a mask, and social distancing to reduce the impact of infection with delta variant B.1,617.2.

References

World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: https://covid19.who.int/.

Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409-24.

Del Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. JAMA. 2021.

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions 2021 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.

Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. MedRXiV. 2021.

Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.

Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. 2020;382(18):1708-20.

Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int. 2020;44(9):1792-7.

Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2(8):1069-76.

Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622-9.

Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies. Nature. 2021:2021.05.08.443253.

Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021;21(10):1352-4.

Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2.

Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. NEJM. 2021;384(15):1412-23.

Downloads

Published

2022-07-07

How to Cite

Nasution, S. A., Muhadi, M., & Tenda, E. D. (2022). Confirmed Delta Variant COVID-19 Infection at A Single Centre Tertiary Hospital: A Case Series. Acta Medica Indonesiana, 54(2), 299. Retrieved from https://actamedindones.org/index.php/ijim/article/view/2024

Issue

Vol. 54 No. 2 (2022): Acta Medica Indonesiana

Section

CASE REPORT

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.